Results 11 to 20 of about 621,365 (219)

Personalized Zebrafish Models for Fusion‐Positive Pediatric Sarcomas

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Clinical sequencing efforts have revolutionized our approaches to categorizing pediatric cancers in real time. This has dramatically improved our ability to profile pediatric tumors, identify actionable vulnerabilities, and influence clinical care.
Lisa H. Hall   +2 more
wiley   +1 more source

Association Between Dinutuximab Beta Exposure and Post‐End‐of‐Treatment Survival in Neuroblastoma: A Weighted Patient‐Level Analysis of Three Clinical Studies

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Objectives The association between exposure to dinutuximab beta (DB) and event‐free survival (EFS) or overall survival (OS) of neuroblastoma patients was assessed using data collected during three clinical trials (five cohorts). Methods A systematic review (March 2026) was conducted to identify relevant studies (prospective; registered DB ...
Przemysław Holko   +19 more
wiley   +1 more source

Impact of Metastatic Patterns on Survival and Response to Therapy in Neuroblastoma

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background While the presence of metastases in neuroblastoma (NB) is a well‐established prognostic factor, the clinical significance of dissemination patterns and tumour burden and their impact on response and survival remains poorly understood.
Mariona Morell‐Daniel   +15 more
wiley   +1 more source

Ovarian Sex Cord Stromal Tumors in Children and Adolescents—The European Standard Clinical Practice Recommendations

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT As part of the European Cooperative Study Group for Paediatric Rare Tumours initiative, we developed standard clinical practice guidelines for ovarian sex cord stromal tumors, based on comprehensive national and international cohort analyses, literature review, and a final expert consensus conference.
Dominik T. Schneider   +15 more
wiley   +1 more source

How to manage KRAS G12C-mutated advanced non-small-cell lung cancer

open access: yesDrugs in Context, 2022
Constitutive KRAS signalling drives tumorigenesis across several cancer types. In non-small-cell lung cancer (NSCLC) activating KRAS mutations occur in ~30% of cases, and the glycine to cysteine substitution at codon 12 (G12C) is the most common KRAS ...
Biagio Ricciuti   +10 more
doaj   +1 more source

Natural Killer Cells in Paediatric Soft Tissue Sarcomas: A Systematic Review

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Paediatric soft tissue sarcomas (pSTS) are a rare and heterogeneous group of malignant tumours arising in tissues of mesenchymal origin. The role of natural killer (NK) cells in pSTS remains poorly understood, with evidence fragmented across small preclinical studies and early‐phase clinical trials.
Raya Dean   +7 more
wiley   +1 more source

Infantile Central Nervous System Juvenile Xanthogranuloma With Somatic CSF1R Mutation Responsive to Imatinib Monotherapy

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Juvenile xanthogranuloma (JXG) of the central nervous system (CNS) is a rare non‐Langerhans cell histiocytosis. CSF1R mutations have been reported for peripheral JXG, but not in CNS JXG. A 3‐month‐old male presented with fever, lymphadenopathy, and macrocephaly with bulging fontanelles.
Sima Vazquez   +8 more
wiley   +1 more source

Synthetic circRNA therapeutics: innovations, strategies, and future horizons

open access: yesMedComm
Small molecule drugs are increasingly emerging as innovative and effective treatments for various diseases, with mRNA therapeutics being a notable representative.
Jingsheng Cai   +9 more
doaj   +1 more source

The Role of Chemotherapy in Pediatric Myoepithelial Carcinoma: A Systematic Review of the Literature

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Myoepithelial carcinoma (MEC) in pediatric patients is a rare and aggressive malignancy characterized by heterogeneous morphology and variable molecular features. The optimal role of chemotherapy remains unclear. We conducted a systematic review according to PRISMA 2020 guidelines to evaluate chemotherapy in pediatric and young‐adult patients ...
Marco Salvi   +7 more
wiley   +1 more source

Chinese Expert Consensus on Second-line Treatment for Non-small Cell Lung Cancer with Negative Driver Gene Mutations

open access: yesChinese Journal of Lung Cancer
For advanced non-small cell lung cancer (NSCLC) patients with negative driver gene mutations, chemotherapy has always been the standard treatment option, and immune checkpoint inhibitors (ICIs) provide other treatment option for these patients.
Expert Committee on Non-small Cell Lung Cancer of the Chinese Society of Clinical Oncology
doaj   +1 more source

Home - About - Disclaimer - Privacy